Trial reportEndoscopy2022
Detection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide.
Trial report in Endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Dissecting oral premalignant carcinogenesis: spatial omics mechanisms and nanomedicine-driven therapeutic innovation.Molecular cancer · 2026Review
- Complementary fluorescence and photoacoustic imaging of tozuleristide in muscle tissue in vitro- toward optically-guided solid tumor surgery: feasibility studies.Scientific reports · 2026Article
- AI-driven pathology in esophageal cancer: from early screening to precision prognostics.Frontiers in oncology · 2026Review
- Tissue-seeking dyes for in vivo applications.Smart molecules : open access · 2024Review
- Intraoperative near infrared functional imaging of rectal cancer using artificial intelligence methods - now and near future state of the art.European journal of nuclear medicine and molecular imaging · 2024Review
- Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation.Molecular & cellular proteomics : MCP · 2024Article
- PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Wide-field endoscope accessory for multiplexed fluorescence imaging.Scientific reports · 2023Article
- Flexible fiber cholangioscope for detection of near-infrared fluorescence.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2023Article
- Application of near-infrared fluorescence imaging in theranostics of gastrointestinal tumors.Gastroenterology report · 2023Review
- Development and Validation of Deep Learning Models for the Multiclassification of Reflux Esophagitis Based on the Los Angeles Classification.Journal of healthcare engineering · 2023Article
- Deep-Learning-Based Real-Time and Automatic Target-to-Background Ratio Calculation in Fluorescence Endoscopy for Cancer Detection and Localization.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEsophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease with poor prognosis that is rising rapidly in incidence. We aimed to demonstrate specific binding by a peptide heterodimer to Barrett's neoplasia in human subjects.
methodsPeptide monomers specific for EGFR and ErbB2 were arranged in a heterodimer configuration and labeled with IRDye800. This near-infrared (NIR) contrast agent was topically administered to patients with Barrett's esophagus (BE) undergoing either endoscopic therapy or surveillance. Fluorescence images were collected using a flexible fiber accessory passed through the instrument channel of an upper gastrointestinal endoscope. Fluorescence images were collected from 31 BE patients. A deep learning model was used to segment the target (T) and background (B) regions.
resultsThe mean target-to-background (T/B) ratio was significantly greater for high grade dysplasia (HGD) and EAC versus BE, low grade dysplasia (LGD), and squamous epithelium. At a T/B ratio of 1.5, sensitivity and specificity of 94.1 % and 92.6 %, respectively, were achieved for the detection of Barrett's neoplasia with an area under the curve of 0.95. No adverse events attributed to the heterodimer were found. EGFR and ErbB2 expression were validated in the resected specimens.
conclusionsThis "first-in-human" clinical study demonstrates the feasibility of detection of early Barrett's neoplasia using a NIR-labeled peptide heterodimer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.